Comparative Pharmacology
Head-to-head clinical analysis: PHISOHEX versus PRE OP II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHISOHEX versus PRE OP II.
PHISOHEX vs PRE-OP II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disrupts bacterial cell wall synthesis by binding to the bacterial ribosome and inhibiting protein synthesis; also has surfactant properties that disrupt bacterial cell membrane integrity.
PRE-OP II (glycopyrrolate and neostigmine) reverses neuromuscular blockade by inhibiting acetylcholinesterase via neostigmine, increasing acetylcholine at the neuromuscular junction, while glycopyrrolate, an anticholinergic, mitigates muscarinic side effects.
Apply topically as a 3% emulsion to affected area, rinse thoroughly; typically used 1-2 times daily for up to 10 days.
1-2 mg/kg IV bolus once preoperatively; maximum dose 100 mg.
None Documented
None Documented
Terminal elimination half-life approximately 6-7 hours in adults with normal renal function. Prolonged in renal impairment (up to 20 hours) due to reduced clearance of active metabolite (pentachlorophenol).
Terminal elimination half-life is 2-4 hours (prolonged in renal impairment; dose adjustment needed for CrCl <30 mL/min)
Renal (biliary/fecal negligible). Up to 10% of dose excreted unchanged in urine; remainder as metabolites (glucuronide and sulfate conjugates).
Renal excretion (98% as unchanged drug), biliary/fecal (<2%)
Category C
Category C
Antiseptic
Antiseptic